|Home | About | Journals | Submit | Contact Us | Français|
Natural vitamin E includes eight chemically distinct molecules: α-, β-, γ- and δ-tocopherol; and α-, β-, γ- and δ-tocotrienol. In the current literature, more than 95% of all studies on vitamin E are directed towards the specific study of α-tocopherol. The other forms of natural vitamin E remain poorly understood. The abundance of α-tocopherol in the human body and the comparable efficiency of all vitamin E molecules as antioxidants, led biologists to neglect the non-tocopherol vitamin E molecules as topics for basic and clinical research. Recent developments warrant a serious reconsideration of this conventional wisdom. The tocotrienol subfamily of natural vitamin E possesses powerful neuroprotective, anti-cancer and cholesterol lowering properties that are often not exhibited by tocopherols. Current developments in vitamin E research clearly indicate that members of the vitamin E family are not redundant with respect to their biological functions. α-Tocotrienol, γ-tocopherol, and δ-tocotrienol have emerged as vitamin E molecules with functions in health and disease that are clearly distinct from that of α-tocopherol. At nanomolar concentration, α-tocotrienol, not α-tocopherol, prevents neurodegeneration. On a concentration basis, this finding represents the most potent of all biological functions exhibited by any natural vitamin E molecule. Recently it has been suggested that the safe dose of various tocotrienols for human consumption is 200-1000 mg/d. A rapidly expanding body of evidence support that members of the vitamin E family are functionally unique. In recognition of this fact, title claims in manuscripts should be limited to the specific form of vitamin E studied. For example, evidence for toxicity of a specific form of tocopherol in excess may not be used to conclude that high-dosage “vitamin E” supplementation may increase all-cause mortality. Such conclusion incorrectly implies that tocotrienols are toxic as well under conditions where tocotrienols were not even considered. The current state of knowledge warrants strategic investment into the lesser known forms of vitamin E. This will enable prudent selection of the appropriate vitamin E molecule for studies addressing a specific health need.
That certain foods are vital to maintaining healthy life was recognized long before the first vitamins were actually identified. In ancient times, the famous Greek physician Hippocrates not only described night blindness, a disease now known to be caused by a vitamin A deficiency, but recommended the eating of “ox liver dipped in honey” as a cure. In the centuries that followed, observers continued to report that certain diseases appeared to be nutritionally related. By and large, they attributed the problem to some unknown “toxic substance” in various foodstuffs. In 1747 when the Scottish physician James Lind proved he could cure scurvy by feeding citrus fruits to stricken sailors, his fellow physicians continued to ignore his work and to search for the “toxin” responsible for the illness. The unknown “toxins” were never found. In the last quarter of the nineteenth century, scientific thinking began to change. In 1886, Christiaan Eijkman, a physician working in the Dutch East Indies, began a serious investigation into beriberi, a thiamine deficiency disease. Eijkman’s studies indicated that beriberi in animals was caused by diets excessively high in polished rice and that it could be cured by substituting unpolished rice. In 1901, a younger colleague, Gerrit Grijns, determined that polished rice lacked an essential “anti-beriberi” substance that could be found in rice hulls and a number of other foods. Contemporary Englishman William Fletcher determined that if special factors (vitamins) were removed from food disease ensued. Fletcher was researching the causes of the disease beriberi when he discovered that eating unpolished rice prevented Beriberi and eating polished rice did not. William Fletcher believed that there were special nutrients contained in the husk of the rice. Next year, English biochemist Sir Frederick Gowland Hopkins also discovered that certain “accessory food factors” were important to health. In 1912, Polish scientist Cashmir Funk named the special nutritional parts of food as a “vitamine” after “vita” meaning life and “amine” from compounds found in the thiamine he isolated from rice husks. Vitamine was later shortened to vitamin when it was discovered that not all of the vitamins contain nitrogen, and, therefore, not all are amines. Together, Hopkins and Funk formulated the vitamin hypothesis of deficiency disease - that a lack of vitamins could make people sick. At this point of time, the notion of fat-soluble vitamins was yet to be conceived.
Fat-soluble vitamins have their root in the 1913 discovery by Elmer V. McCollum, Thomas B. Osborne and Lafayette B. Mendel who isolated a growth-producing substance from egg yolks. The substance appeared quite different from the water-soluble vitamins already discovered. In 1916, McCollum went on to show that at least two factors were responsible for the normal growth of rats, factors he named fat-soluble A and water-soluble B. McCollum therefore is credited with initiating the custom of labeling vitamins by letters. Vitamin E was discovered in 1922 in green leafy vegetables by University of California researchers, Herbert Evans and Katherine Bishop (Evans and Bishop 1922). In 1924, Sure named it vitamin E. Because E supported fertility, it was scientifically named tocopherol. This comes from the Greek word tokos meaning childbirth, and phero meaning to bring forth, and the ol ending was added to indicate the alcohol properties of this molecule. In 1936 it was discovered that vitamin E was abundant in wheat germ oil. Two years later, it was chemically synthesized for the first time. The U.S. National Research Council sponsored studies on deficiencies of vitamin E, and based on the results E was designated an essential vitamin. Vitamin E emerged as an essential, fat-soluble nutrient that functions as an antioxidant in the human body. It is essential, because it is required to sustain life and the body cannot manufacture its own vitamin E and foods and supplements must provide it. Since the elucidation of the chemical structure of vitamin E in 1938 by Fenholz and the synthesis of dl-α-tocopherol by Karrer in the same year, specific focus was directed on the chemical class of natural compounds that qualify to be vitamin E. Vitamin E was rediscovered as factor 2 antioxidant in 1965 (Schwarz 1965). α-Tocopherol drew most attention as the first natural form of vitamin E identified while its sisters remained under veil. At present, vitamin E represents a generic term for four tocopherols and four tocotrienols (Bruno and Traber 2006). In nature, eight substances have been found to have vitamin E activity: α-, β-, γ- and δ-tocopherol; and α-, β-, γ- and δ-tocotrienol. Although it has been claimed that tocotrienol may be metabolized to tocopherol in the human tissue (Qureshi et al., 2001c; Qureshi et al., 2002), the concept has not gained wide acceptance and the hypothesis remains open for additional considerations.
Tocopherols consist of a chromanol ring and a 15-carbon tail derived from homogentisate (HGA) and phytyl diphosphate, respectively (Fig. 1). Condensation of HGA and phytyl diphosphate, the committed step in tocopherol biosynthesis, is catalyzed by HGA phytyltransferase (HPT)(Venkatesh et al., 2006). Tocopherol helps maintain optimal photosynthesis rate under high-light stress (Porfirova et al., 2002). Tocotrienols differ structurally from tocopherols by the presence of three trans double bonds in the hydrocarbon tail. Because of these unsaturations in the isoprenoid side-chain, tocotrienols are thought to assume a unique conformation (Atkinson 2006). α-Tocotrienol seems to be very likely much more flexible in the sidechain and that it puts a greater curvature stress on phospholipid membranes. This has been confirmed in scanning calorimetry data (unpublished personal communication by Dr. Jeffrey Atkinson).
Tocotrienols are the primary form of vitamin E in the seed endosperm of most monocots, including agronomically important cereal grains such as wheat, rice, and barley. Palm oil contains significant quantities of tocotrienol (Sundram et al., 2003). Tocotrienols are also found in the seed endosperm of a limited number of dicots, including Apiaceae species and certain Solanaeceae species, such as tobacco. These molecules are found only rarely in vegetative tissues of plants. Crude palm oil extracted from the fruits of Elaeis guineensis particularly contains a high amount of tocotrienols (up to 800 mg/kg), mainly consisting of γ-tocotrienol and α-tocotrienol. Compared to tocopherols, tocotrienols are considerably less widespread in the plant kingdom (Horvath et al., 2006). In 80 different plant species studied, twenty-four were found to contain significant amounts of tocotrienols. No taxonomic relation was apparent among the 16 dicotyledonous species that were found to contain tocotrienol. Monocotyledonous species (eight species) belonged either to the Poaceae (six species) or the Aracaceae (two species). A more detailed analysis of tocotrienol accumulation revealed the presence of this natural vitamin E in several non-photosynthetic tissues and organs, i.e. seeds, fruits and in latex. No tocotrienols could be detected in mature photosynthetic tissues. Transient accumulation of low levels of tocotrienols is found in the young coleoptiles of plant species whose seeds contained tocotrienols. No measurable tocotrienol biosynthesis was apparent in coleoptiles, or in chloroplasts isolated from such coleoptiles. Tocotrienol accumulation in coleoptiles was not associated with chloroplasts. Tocotrienols seem to be transiently present in photosynthetically active tissues, however, it remains to be proven whether they are biosynthesized in such tissues, or imported from elsewhere in the plant (Horvath et al., 2006).
In contrast to tocotrienols, tocopherols occur ubiquitously in plant tissues and are the exclusive form of vitamin E in leaves of plants and seeds of most dicots. Transgenic expression of the barley HGGT (homogentisic acid transferase, which catalyzes the committed step of tocotrienol biosynthesis)in Arabidopsis thaliana leaves resulted in accumulation of tocotrienols, which were absent from leaves of non-transformed plants, and a 10- to 15-fold increase in total vitamin E antioxidants (tocotrienols plus tocopherols). Overexpression of the barley HGGT in corn seeds resulted in an increase in tocotrienol and tocopherol content of as much as six-fold. These results provide insight into the genetic basis for tocotrienol biosynthesis in plants and demonstrate the ability to enhance the antioxidant content of crops by introduction of an enzyme that redirects metabolic flux (Cahoon et al., 2003). More recently, another strategy involving genetic engineering of metabolic pathways in plants has proved to be efficient in bolstering tocotrienol biosynthesis (Rippert et al., 2004). In plants, phenylalanine is the precursor of a myriad of secondary compounds termed phenylpropanoids. In contrast, much less carbon is incorporated into tyrosine that provides p-hydroxyphenylpyruvate and homogentisate, the aromatic precursors of vitamin E. The flux of these two compounds has been upregulated by deriving their synthesis directly at the level of prephenate. This was achieved by the expression of the yeast prephenate dehydrogenase gene in tobacco plants that already over-express the Arabidopsis p-hydroxyphenylpyruvate dioxygenase coding sequence. Massive accumulation of tocotrienols was observed in leaves. These molecules, which were undetectable in wild-type leaves, became the major forms of vitamin E in the leaves of the transgenic lines. An increased resistance of the transgenic plants toward the herbicidal p-hydroxyphenylpyruvate dioxygenase inhibitor diketonitril was also observed. Thus, the synthesis of p-hydroxyphenylpyruvate is a limiting step for the accumulation of vitamin E in plants (Rippert et al., 2004).
A striking asymmetry in our understanding of the eight-member natural vitamin E tocol family has deprived us of the full complement of benefits offered by the natural vitamin E molecules (Fig. 2). Approximately only 1% of the entire literature on vitamin E addresses tocotrienols. A review of the NIH CRISP database shows that funding for tocotrienol research represents less than 1% of all vitamin E research during the last 30+ years. Within the tocopherol literature, the non-α forms remain poorly studied (Dietrich et al., 2006; Hensley et al., 2004; O’Byrne et al., 2000). This represents a major void in vitamin E research. It is important that conclusions drawn about the usefulness of vitamin E as a whole to human health be drawn in this light. At present, conclusions drawn about vitamin E as whole in light of results from α–tocopherol studies alone (Friedrich 2004; Gorman 2005; Greenberg 2005; Hathcock et al., 2005; Miller et al., 2005) can be misleading. It is important to recognize the gaping voids in our understanding of the non-α-tocopherol forms of vitamin E and develop a more symmetrical understanding which would enable us to pick the right form of vitamin E for specific health indications. In this context we need to be cognizant of the fact the biological functions of the different homologues of natural vitamin E are not identical. Evidence supporting the unique biological significance of vitamin E family members is provided by current results derived from α-tocotrienol research. During the last 5 years, tocotrienol research has gained substantial momentum (Fig. 2). More than two-thirds (189/280) of the entire PubMed literature on tocotrienols has been published on or after 2000. This represents a major swing in the direction of vitamin E research.
All eight tocols in the vitamin E family share close structural similarity (Fig. 1) and hence comparable antioxidant efficacy. Yet, current studies of the biological functions of vitamin E continue to indicate that members of the vitamin E family possess unique biological functions often not shared by other family members. One of the earliest observations suggesting that α-tocopherol may have functions independent of its antioxidant property came from the study of platelet adhesion. α-Tocopherol strongly inhibits platelet adhesion. Doses of 400 IU/day provide greater than 75% inhibition of platelet adhesion to a variety of adhesive proteins when tested at low shear rate in a laminar flow chamber. The antiadhesive effect of α-tocopherol appears to be related to a reduction in the number and size of pseudopodia upon platelet activation and this finding led to the hypothesis that within the body vitamin E may exert functions beyond its antioxidant property (Steiner 1993). That members of the tocopherol family may have functions independent of their antioxidant properties gained more prominence when vitamin E molecules with comparable antioxidant properties exhibited contrasting biological effects (Boscoboinik et al., 1991). At the post-translational level, α-tocopherol inhibits protein kinase C, 5-lipoxygenase and phospholipase A2 and activates protein phosphatase 2A and diacylglycerol kinase. Some genes (e.g. scavenger receptors, α-TTP, α-tropomyosin, matrix metalloproteinase-19 and collagenase) are specifically modulated by α-tocopherol at the transcriptional level. α-Tocopherol also inhibits cell proliferation, platelet aggregation and monocyte adhesion. These effects have been characterized to be unrelated to the antioxidant activity of vitamin E, and possibly reflect specific interactions of α-tocopherol with enzymes, structural proteins, lipids and transcription factors (Zingg and Azzi 2004). γ-Tocopherol represents the major form of vitamin E in the diet in the USA, but not in Europe. Desmethyl tocopherols, such as γ-tocopherol and specific tocopherol metabolites, most notably the carboxyethyl-hydroxychroman (CEHC) products, exhibit functions that are not shared by α-tocopherol. The activities of these other tocopherols do not map directly to their chemical antioxidant behavior but rather reflect anti-inflammatory, antineoplastic, and natriuretic functions possibly mediated through specific binding interactions (Hensley et al., 2004). Metabolites of γ-tocopherol (2,7,8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman), but not that of α-tocopherol, provides natriuretic activity. Moreover, a nascent body of epidemiological data suggests that γ-tocopherol is a better negative risk factor for certain types of cancer and myocardial infarction than is α-tocopherol (Wagner et al., 2004).
α-Tocotrienol possesses numerous functions that are not shared by α-tocopherol (Sen et al., 2006). For example, nanomolar concentrations of α-tocotrienol uniquely prevent inducible neurodegeneration by regulating specific mediators of cell death (Khanna et al., 2006; Khanna et al., 2003; Sen et al., 2000). Oral supplementation of tocotrienol protects against stroke (Khanna et al., 2005b). Micromolar amounts of tocotrienol suppress the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for cholesterol synthesis (Pearce et al., 1994; Pearce et al., 1992). Tocopherols do not share the cholesterol-lowering properties of tocotrienol (Qureshi et al., 1986; Qureshi et al., 2002). Sterol-regulated ubiquitination marks HMG-CoA reductase for endoplasmic reticulum (ER)-associated degradation by 26S proteasomes. This degradation, which results from sterol-induced binding of reductase to ER membrane proteins called Insigs, contributes to the complex, multivalent feedback regulation of the enzyme. Recently it has been demonstrated that δ-tocotrienol stimulates ubiquitination and degradation of reductase and blocks processing of sterol regulatory element-binding proteins (SREBPs), another sterol-mediated action of Insigs. The γ-tocotrienol analog is more selective in enhancing reductase ubiquitination and degradation than blocking SREBP processing. Other forms of vitamin E neither accelerate reductase degradation nor block SREBP processing (Song and Debose-Boyd 2006).
Tocotrienol, not tocopherol, administration reduces oxidative protein damage and extends the mean life span of C. elegans (Adachi and Ishii 2000). Tocotrienols are thought to have more potent antioxidant properties than α-tocopherol (Serbinova et al., 1991; Serbinova and Packer 1994). The unsaturated side chain of tocotrienol allows for more efficient penetration into tissues that have saturated fatty layers such as the brain and liver (Suzuki et al., 1993). Experimental research examining the antioxidant, free radical scavenging effects of tocopherol and tocotrienols revealed that tocotrienols appear superior due to their better distribution in the fatty layers of the cell membrane (Suzuki et al., 1993). Furthermore, tocotrienol but not tocopherol, suppresses growth of human breast cancer cells (Nesaretnam et al., 1995).
In humans, tocotrienol supplementation results in peak blood plasma level of α-tocotrienol that is over an order of magnitude higher than that required to protect neurons against a range of neurotoxic insults (Khanna et al., 2005a; Khanna et al., 2006; Khanna et al., 2003; Khanna et al., 2005b; Khosla et al., 2006; Sen et al., 2000). Despite such promising potential, tocotrienol research accounts for roughly 1% of all vitamin E research published in PubMed. The unique vitamin action of α-tocopherol, combined with its prevalence in the human body and the similar efficiency of tocopherols as chain-breaking antioxidants, led biologists to almost completely discount the “minor” vitamin E molecules as topics for basic and clinical research. Recent discoveries warrant a serious reconsideration of this conventional wisdom.
Tocotrienol is synthesized in edible as well as inedible plant products. Rubber latex represents a major non-food natural source of tocotrienols (Chow and Draper 1970; Horvath et al., 2006; Whittle et al., 1966). Identification of α-tocotrienol as a cholesterogenesis-inhibitory factor in barley (Hordeum vulgare L.) represents a landmark early discovery highlighting the unique significance of tocotrienols in health and disease (Qureshi et al., 1986). Purification of an oily, non-polar fraction of high protein barley flour by high pressure liquid chromatography yielded 10 major components. Two of these components were identified as potent inhibitors of cholesterogenesis both in vivo as well as in vitro. Addition of the purified inhibitor I (2.5-20 ppm) to chick diets significantly decreased hepatic cholesterogenesis and serum total and low density lipoprotein cholesterol and concomitantly increased lipogenic activity. The high resolution mass spectrometric analysis and measurement of different peaks of inhibitor I gave a molecular ion at m/e 424 (C29H44O2) and main peaks at m/e 205, 203, and 165 corresponding to C13H17O2, C13H15O2, and C10H13O2 moieties, respectively. Based on these results, d-α-tocotrienol was identified as the active principle. This identification was confirmed against synthetic samples (Qureshi et al., 1986).
Palm oil represents one of the most abundant natural sources of tocotrienols (Elson 1992). The distribution of vitamin E in palm oil is 30% tocopherols and 70% tocotrienols (Sundram et al., 2003). The oil palm (Elaeis guineensis) is native to many West African countries, where local populations have used its oil for culinary and other purposes. Large-scale plantations, established principally in tropical regions of Asia, Africa and Latin America are mostly aimed at the production of oil (Solomons and Orozco 2003), which is extracted from the fleshy mesocarp of the palm fruit, and endosperm or kernel oil. Palm oil is different from other plant and animal oils in that it contains 50% saturated fatty acids, 40% unsaturated fatty acids, and 10% polyunsaturated fatty acids. Because of its high saturated fat content, palm oil has not been very popular in the United States. Hydrogenated fats contain high levels of trans-fatty acids which are now thought to have adverse health effects. The US Food and Drug Administration’s final ruling on trans-fatty acid labeling issued in 2003 has caused a rapid transformation in the fat and oil industries (Tarrago-Trani et al., 2006). Palm oil is free of trans-fatty acid and is rapidly gaining wider acceptance by the food industry in the country. Primary applications include bakery products, breakfast cereals, wafers and candies.
Rice bran oil, a by-product of the rice milling industry, is a major natural source of γ-tocotrienol but a poor source of α-tocotrienol. In addition, rice bran oil provides desmethyl tocotrienols. Two novel tocotrienols were isolated from stabilized and heated rice bran, apart from the known α-, β-, γ-, and δ-tocopherols and tocotrienols. These new tocotrienols are known as desmethyl tocotrienol [3, 4-dihydro-2-methyl-2-(4,8,12-trimethyltrideca-3’(E),7’(E), 11’-trienyl)-2H-1-benzopyran-6-ol] and didesmethy tocotrienol [3, 4-dihydro-2-(4,8,12-trimethyltrideca-3’(E),7’(E), 11’-trienyl)-2H-1-benzopyran-6-ol] (Qureshi et al., 2000). Although scientific evidence is relatively limited, rice bran oil (RBO) is tenaciously believed to be a healthy vegetable oil in Asian countries (Sugano et al., 1999).
Cereals such as oat, rye and barley contain small amounts of tocotrienol in them. α-Tocotrienol is the predominant form of tocotrienol in oat (Avena sativa L.) and barley (56 and 40 mg/kg of dry weight, respectively). β-Tocotrienol is the major form of tocotrienol found in hulled and dehulled wheats (from 33 to 43 mg/kg of dry weight) (Panfili et al., 2003). Steaming and flaking of dehulled oat groats results in moderate losses of tocotrienols but not of tocopherols (Bryngelsson et al., 2002). Autoclaving of grains (including the hulls) increases the levels of all tocopherols and tocotrienols analyzed except β-tocotrienol, which was not affected. Drum drying of steamed rolled oats results in an almost complete loss of tocopherols and tocotrienols (Bryngelsson et al., 2002). Although tocotrienols are present in edible natural products, it is questionable whether these dietary sources could provide sufficient amounts of tocotrienol to humans. Of note, processing of 1000 kg of crude palm oil is necessary to derive 1 kg of the commercial product Tocomin 50% (Carotech, NJ). Roughly, one would have to consume 100-200g of palm/rice-bran oil or 1.5-4 kg of wheat-germ, barley or oat to achieve doses that have been published to be effective biologically. With this consideration in mind, appropriately configured dietary supplements seem to be a prudent choice.
During the last two decades, efforts to understand how dietary vitamin E is transported to the tissues have focused on α-tocopherol transport (Blatt et al., 2001; Kaempf-Rotzoll et al., 2003; Traber and Arai 1999; Traber et al., 2004). α-Tocopherol transfer protein (TTP) has been identified to mediate α–tocopherol secretion into the plasma while other tocopherol-binding proteins seem to play a less important role (Kaempf-Rotzoll et al., 2003). Tocotrienols have been known for decades but why have they not been studied as well as α–tocopherol? Although there does not seem to be straightforward rational answer to this question, one contributing factor is whether tocotrienol taken orally reaches vital organs of the body. This concern was primarily based on a 1997 finding that the transport system, α-tocopherol transport protein (TTP), responsible to carry α-tocopherol to vital organs has a poorer efficiency to transport tocotrienols to tissues (Hosomi et al., 1997). The lack of relative specific affinity of TTP for tocotrienols led to the notion that availability of dietary tocotrienol to vital organs is negligible.
TTP is a soluble 32-kDa protein expressed in liver that selectively binds and transports α–tocopherol. TTP maintains the concentration of serum α–tocopherol by facilitating α–tocopherol export from the liver. TTP is required to maintain normal α–tocopherol concentrations in plasma and extrahepatic tissues (Traber et al., 2004). Although TTP is known to bind to α–tocotrienol with 8.5-fold lower affinity than that for α–tocopherol (Hosomi et al., 1997), it has not been clear whether, or to what extent, the delivery of orally supplemented α–tocotrienol to vital organs is dependent on TTP. Previously it has been reported that TTP deficient females are infertile presumably because of vitamin E deficiency (Terasawa et al., 2000). This important observation was confirmed in a lineage of TTP deficient mice. Placenta of pregnant TTP deficient females were severely impaired with marked reduction of labyrinthine trophoblasts, and the embryos died at mid-gestation even when fertilized eggs of TTP-containing wild-type mice were transferred into TTP-deficient recipients (Jishage et al., 2001). Even in the presence of dietary α-tocopherol, TTP knock-out mice are known to suffer from α-tocopherol deficiency (Jishage et al., 2001; Terasawa et al., 2000). Recently it has been noted that oral supplementation of female mice with α–tocotrienol restored fertility of TTP knock-out mice suggesting that tocotrienol was successfully delivered to the relevant tissues and that tocotrienol supported reproductive function under conditions of α–tocopherol deficiency (Khanna et al., 2005a). This observation was consistent with another line of evidence from rats where tocotrienol supplementation spared loss of fertility caused by long-term vitamin E deficiency in the diet (Khanna et al., 2005a). TTP continues to be a key transport mechanism for the deliver of α-tocopherol to tissues. The significance of TTP in the transport of other forms of vitamin E remains unclear at present. It is clear, however, that natural isomers of vitamin E do get transported to vital organs even in the absence of TTP. Identification and characterization of TTP-independent vitamin E transport mechanisms in vivo is warranted.
Ten years ago in a study testing ligand specificity of vitamin E isomers for TTP concluded that the affinity of vitamin E analogs for TTP is one of the critical determinants of their biological activity (Hosomi et al., 1997). This conclusion was based on the assumption that the biological function of vitamin E molecules is proportionate to their concentration and that vitamin E isomers have redundant function. Early postulates proposing that tissue concentration and relative biologic function of tocopherol and tocotrienol are disparate and possibly unrelated (Hayes et al., 1993). Developments during the last decade taught us that both assumptions are incorrect warranting a revisit of the fundamental principles that guide vitamin E research (Azzi et al., 1995; Azzi and Stocker 2000; Sen et al., 2004; Sen et al., 2006). Another contemporary study reported that tocotrienols, supplemented to laboratory chow, do not reach the brain (Podda et al., 1996). Taken together, the case for in vivo efficacy of oral tocotrienol was seriously weakened by these reports (Hosomi et al., 1997; Podda et al., 1996). Today, however, the scenario has strikingly changed in light of new knowledge. For example, it is now clear that oral tocotrienol not only reaches the brain (Khanna et al., 2005a; Khanna et al., 2005b; Roy et al., 2002) but it does so in amounts sufficient to protect against stroke (Khanna et al., 2005b). The standard laboratory chow contains excessive amounts of α-tocopherol (Khosla et al., 2006; van der Worp et al., 1998) but negligible amounts of tocotrienol. Long-term lack of tocotrienol in the diet may repress any putative tocotrienol transport mechanism in vivo. Thus, long-term supplementation studies are needed. In light of the knowledge that natural analogs of vitamin E may compete for specific transporting mechanisms (Hosomi et al., 1997), it is important that tocotrienol supplementation be performed under conditions of minimized co-presence of tocopherols. Another related consideration is that although incorporation of orally supplemented vitamin E into tissues is a slow and progressive process, rapid incorporation of the supplement into tissues of newborns may occur in response to gavaging of pregnant mother rats (Roy et al., 2002). Thus, an experimental design incorporating long-term tocotrienol supplementation under conditions of minimal dietary co-presence of tocopherols and breeding of the supplemented colony would be a valuable approach to generate proof of principle testing whether dietary α–tocotrienol is capable of being transported to vital organs in vivo. In a recent study rats were maintained on vitamin E deficient diet and gavaged with α–tocotrienol alone, α–tocopherol alone or in combination. Five generations of rats were studied over sixty weeks (Khanna et al., 2005a). Skin, adipose, heart, lungs, skeletal muscle brain, spinal cord, liver and blood were studied. Oral tocotrienol was delivered to all vital organs. In some tissues, the level of tocotrienol exceeded that of tocopherols indicating the presence of an efficient tocotrienol transport system in vivo. Baseline levels of α–tocotrienol in the skin of tocopherol-fed rats that never received any tocotrienol supplementation were negligible. Orally supplemented tocotrienol was rapidly taken up by the skin. Already in second generation rats, α–tocotrienol levels in the skin of tocotrienol supplemented rats exceeded twice the α–tocopherol levels in that organ. Of note, the α–tocotrienol level in the skin matched the α–tocotrienol level in the skin of rats fed with a comparable amount of tocopherol. When tocotrienol and tocopherol were co-supplemented, the uptake of α–tocotrienol by the skin was clearly blunted. In this group, α–tocotrienol levels were lower than α–tocotrienol levels in the skin suggesting a direct competition between orally taken tocotrienol and tocopherol for delivery to the skin. Longer supplementation resulted in a marked increase in the α–tocotrienol levels in the skin of tocotrienol-fed rats indicating a build-up of α–tocotrienol over time. Interestingly, the levels of α–tocotrienol in the skin of these rats were folds higher than the α–tocopherol level in the skin of tocopherol-fed rats. This observation suggests the presence of an effective transport mechanism delivering α–tocotrienol to the skin and efficient retention of α–tocotrienol in the skin over time. Co-supplementation of tocotrienol and tocopherol demonstrated favorable uptake of α–tocopherol over α–tocotrienol. Adipose tissue serves as storage organ for vitamin E (Adachi et al., 1990). Analysis of adipose tissue vitamin E content of fifth generation rats revealed substantially more accumulation of α–tocotrienol in that tissue than α–tocopherol.
In the case of tocotrienol as well as of tocopherol feeding, results from third and fifth generation rats indicate higher levels of vitamin E in the skin of female compared to that of male rats. This gender-specific effect suggesting better transport of tocotrienol in females than in males was noted as a general trend across all organs studied. Gender-based differences in the transport of dietary vitamins are known to exist in specific cases (Garry et al., 1987). Although the effect of several physiological factors on vitamin E transport has been studied, the gender factor remains to be specifically addressed (Lodge et al., 2004). Recently it has been demonstrated that γ-tocopherol is more rapidly metabolized in women than in men (Leonard et al., 2005). The level of α–tocotrienol in the ovary was over five-fold higher than that in the testes from the corresponding males rats (Khanna et al., 2005a). In the ovary, tocopherol is known to accumulate via a lipoprotein receptor dependent mechanism (Aten et al., 1994). Whether tocotrienol shares that mechanism remain to be tested.
Vitamin E enters the circulation from the intestine in chylomicrons. The conversion of chylomicrons to remnant particles results in the distribution of newly absorbed vitamin E to all of the circulating lipoproteins and ultimately to tissues. This enrichment of lipoproteins with vitamin E is a key mechanism by which vitamin E is delivered to tissues (Traber et al., 2004). In the liver, newly absorbed dietary lipids are incorporated into nascent very low density lipoproteins. The liver is responsible for the control and release of α-tocopherol into blood plasma. In the absence of TTP, α-tocopherol is not secreted back into the plasma. Excess vitamin E is not accumulated in the liver, but is excreted, mostly in bile (Traber et al., 2004). Recently it has been noted that α–tocotrienol levels in the liver of rats and of TTP-deficient mice was much lower than the levels of this vitamin E isoform in most peripheral tissues studied (Khanna et al., 2005a). Such observation argues against a central role of the liver in delivering oral α–tocotrienol to peripheral tissues. TTP has the ability to bind to both α–tocopherol as well as α–tocotrienol. The affinity to bind α–tocopherol is several-fold higher than that for α–tocotrienol (Hosomi et al., 1997). Thus, under conditions of co-existence, α–tocopherol is expected to out-compete α–tocotrienol for binding. Although studies with the TTP-deficient mice (Khanna et al., 2005a) indicate the existence of a TTP-independent mechanisms for the tissue delivery of oral α–tocotrienol, observations in the rat (Khanna et al., 2005a) indicate that the mechanisms for transporting α–tocopherol and α–tocotrienol seem to compete such that transport of α–tocopherol is favored. Thus, co-supplementation of α–tocopherol and α–tocotrienol is likely to compromise tissue delivery of α–tocotrienol (Khanna et al., 2005a).
Few studies have specifically looked at the fate of oral tocotrienol supplementation in humans. In a study investigating the pharmacokinetics and bioavailability of α-, γ- and δ-tocotrienols under fed and fasted conditions in eight healthy volunteers, subjects were administered a single 300 mg oral dose of mixed tocotrienols under fed or fasted conditions. The peak concentration of α-tocotrienol in the blood plasma was just over 1μM (Yap et al., 2001). The fed state increased the onset as well as the extent of absorption of tocotrienols by more than two folds. In addition, the mean apparent elimination half-life of α-, γ- and δ-tocotrienols was estimated to be 4.4, 4.3 and 2.3 h, respectively, being between 4.5- to 8.7-fold shorter than that reported for α-tocopherol (Yap et al., 2001). In another study, human subjects took tocotrienyl acetate supplements (250 mg/d) for eight weeks while being on low-fat diet. In response to supplementation, the concentrations of tocotrienol in the mean blood plasma were as follows: α-tocotrienol, 0.98 μM; γ-tocotrienol, 0.54 μM; and δ-tocotrienol 0.09 μM (O’Byrne et al., 2000). Thus, tocotrienyl acetate supplements were observed to be hydrolyzed, absorbed, and detectable in human plasma. Recently, a novel formulation for improved absorption of tocotrienols has been developed (Ho et al., 2003). Emulsions are known to increase absorption of fat-soluble drugs. This invention is based on SEDDS (self-emulsifying drug delivery systems) technology (Araya et al., 2006; Gao and Morozowich 2006; Hong et al., 2006). Soft-gelatin capsules (Tocovid Suprabio™) containing tocotrienol have been produced. Once ingested, the tocotrienols form emulsion when the contents are released and mixed with human gastrointestinal fluid. In a recent study using Tocovid Suprabio™ the post-absorptive fate of tocotrienol isomers and their association with lipoprotein subfractions was examined in humans (Khosla et al., 2006). The peak α-tocotrienol concentrations in supplemented individuals averaged approximately 3 microM in blood plasma, 1.7 microM in LDL, 0.9 microM in triglyceride-rich lipoprotein, and 0.5 microM in HDL. This peak plasma concentration of α-tocotrienol is 2-3 times more than the peak concentration reported in previous studies using generic supplements not based on SEDDS (O’Byrne et al., 2000; Yap et al., 2001).
The biological functions of tocotrienol known so far have been listed in Table 1. In this section, we discuss work that relate to the neuroprotective, anti-cancer and cholesterol-lowering activities of tocotrienol.
Glutamate-toxicity is a major contributor to neurodegeneration. It includes excitotoxicity and an oxidative stress component also known as oxytosis (Schubert and Piasecki 2001; Tan et al., 2001). Murine HT hippocampal neuronal cells, lacking intrinsic excitotoxicity-pathway, have been used as a standard model to characterize the oxidant-dependent component of glutamate toxicity. In 1999, we conducted a side by side comparison of all eight forms of natural vitamin E in a model of glutamate-induced neurodegeneration of HT neural cells. In subsequent experiments it was observed that the neuroprotective property of tocotrienol applies not only to neural cell lines but also to primary cortical neurons. This line of experimentation led to an observation that eventually turned out to be the most potent function of any natural form of vitamin E on a concentration basis reported. Until then, all biological functions of vitamin E studied in vitro were observed at micromolar concentration. Our studies led to the first evidence that α-tocotrienol was the most potent neuroprotective form of vitamin E in glutamate-induced degeneration of HT4 hippocampal neurons (Sen et al., 2000). What was striking in this study was the observation that nanomolar concentrations of α-tocotrienol, not α-tocopherol, provide complete neuroprotection. At such low dose, tocotrienol was not protective against direct oxidant insult suggesting that the observed neuroprotective effects of nanomolar tocotrienol was not dependent on the widely known antioxidant property of vitamin E. That tocotrienol-dependent neuroprotection includes a significant antioxidant-independent mechanism has been now established (Khanna et al., 2006). The neuroprotective property of tocotrienol holds good not only in response to glutamate challenge but also in response to other insults such as homocysteic acid, glutathione deficiency, and linoleic acid induced oxidative stress (Khanna et al., 2006; Sen et al., 2000). It is now evident that at micromolar concentrations tocotrienol protects neural cells by virtue of its antioxidant property. At nanomolar concentrations, however, tocotrienol regulates specific neurodegenerative signaling processes.
The major tocotrienol-sensitive signaling pathways which are known to be involved in glutamate-induced neurodegeneration include c-Src and 12-lipoxygenase (Khanna et al., 2006; Khanna et al., 2003; Khanna et al., 2005b; Sen et al., 2004; Sen et al., 2000). In our initial search for signaling pathways that are sensitive to tocotrienol and play a decisive role in neurodegeneration we were led to c-Src kinase (Sen et al., 2000). c-Src and the structurally related members of the Src family are non-receptor tyrosine kinases that reside within the cell associated with cell membranes and appear to transduce signals from transmembrane receptors to the cell interior. SH2 and SH3 domains are known to play a central role in regulating the catalytic activity of src protein tyrosine kinase. High-resolution crystal structures of human Src, in their repressed state, have provided a structural explanation for how intramolecular interactions of the SH3 and SH2 domains stabilize the inactive conformation of Src (Thomas and Brugge 1997).
Our hypothesis that tocotrienol prevents neurodegeneration by regulating specific signaling processes involved in neurotoxicity led to screening for potential tocotrienol-sensitive candidate death pathways in HT4 cells. During such screening studies, inhibitors of the protein tyrosine kinase activity completely prevented glutamate-induced cell death. Herbimycin and geldanamycin potently inhibit c-Src tyrosine kinase activity (Hall et al., 1994; Yoneda et al., 1993) whereas lavendustin A is an inhibitor of extracellular growth factor receptor protein tyrosine kinase activity (Hsu et al., 1991). The observation that herbimycin and geldanamycin, but not lavendustin A prevented glutamate-induced death of HT4 neuronal cells hinted the involvement of c-Src kinase activity in the death pathway. Immunoprecipitation of tyrosine phosphorylated protein from cellular extracts confirmed that protein tyrosine phosphorylation reactions were indeed triggered by exposure of cells to elevated levels of glutamate, and that such reactions were inhibited by nanomolar concentrations of α-tocotrienol (Sen et al., 2000). These results, however, did not provide any information regarding the specific kinases involved. The involvement of c-Src kinase activity in the death pathway was verified by experiments involving the over-expression of catalytically active or inactive src kinase. Indeed, over-expression of catalytically active Src-kinase markedly sensitized the cells to HT4 induced death. Tocotrienol treatment completely prevented glutamate-induced death even in active c-Src kinase over-expressing cells indicating that it either inhibited c-Src kinase activity or regulated one or more events upstream of c-Src kinase activation. Further evidence supporting this contention was provided by results obtained from the determination of c-Src kinase activity in HT4 cells. Glutamate treatment resulted in marked enhancement of c-Src kinase activity, and this change was completely blocked in cells treated with nanomolar amounts of α-tocotrienol. Further evidence establishing that signal transduction processes related to the cell death pathway are involved in glutamate-induced cytotoxicity was obtained from the study of ERK1 and ERK2 activation. Mitogen-activated/extracellular response kinase kinase (MEK) kinase (MEKK) is a serine-threonine kinase that regulates sequential protein phosphorylation pathways, leading to the activation of mitogen- activated protein kinases (MAPK), including members of the extracellular signal-regulated kinases (ERKs). MEKK selectively regulates signal transduction pathways that contribute to the apoptotic response (Johnson et al., 1996). When activated, p44 and p42 MAPK (ERK1 and ERK2) are phosphorylated at specific threonine and tyrosine residues. ERK has been implicated in mediating the signaling events that precede apoptosis. ERK2 plays an active role in mediating anti-IgM-induced apoptosis of B cells (Lee and Koretzky 1998). It has been also shown that H2O2 induces the activation of multiple MAPKs in oligodendrocyte progenitors and that the activation of ERK is associated with oxidant- mediated cytotoxicity (Bhat and Zhang 1999). Our studies showed that ERK1 and 2 are sensitive to elevated levels of extracellular glutamate. Rapid activation of ERK, particularly ERK2, was observed in response to glutamate treatment. Such response of ERK was completely inhibited in cells treated with α-tocotrienol suggesting that α-tocotrienol influences an early event in the glutamate-induced death pathway (Sen et al., 2000). In some cases Src kinase activity is known to be required for the activation of ERK (Aikawa et al., 1997). Thus, it is likely tocotrienol inhibits inducible ERK activation by down-regulating Src kinase activity (Sen et al., 2000).
c-Src is heavily expressed in the brain (Soriano et al., 1991) and in human neural tissues (Pyper and Bolen 1989). Differentiating rodent neurons are known to express high levels of c-Src. In neurons and astrocytes, c-Src is present at 15-20 times higher levels than that found in fibroblasts. The specific activity of the c-Src protein from neuronal cultures is 6-12-times higher than that from the astrocyte cultures suggesting a key function of this protein in neurons (Brugge et al., 1985). Initially, c-Src was identified as being important in growth cone-mediated neurite extension and synaptic plasticity (Maness et al., 1988) and in neuronal differentiation (Ingraham et al., 1989). Targeted disruption of c-Src, however, did not cause any abnormality in the brain (Soriano et al., 1991). Our pursuit for the neuroprotective mechanisms of tocotrienols led to the first evidence demonstrating that rapid c-Src activation (Khanna et al., 2002; Sen et al., 2000) plays a central role in executing neurodegeneration. Consistently, it was demonstrated in a subsequent report that Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke (Paul et al., 2001). Further support of our claim that c-Src is a key player in neurodegeneration is provided by observation that the Src family kinase-inhibitor PP2 reduces focal ischemic brain injury (Lennmyr et al., 2004). Our observation that tocotrienol-dependent inhibition of c-Src is beneficial for neuroprotection has now been extended to the heart. A recent study showed that c-Src mediates post-ischemic cardiac injury and dysfunction. Tocotrienol supplementation inhibited c-Src activation and protected the heart (Das et al., 2005). Many intracellular pathways can be stimulated upon Src activation, and a variety of cellular consequences can result. High c-Src is tightly associated with carcinogenesis. c-Src inhibitors are being actively studied for cancer therapy (Alper and Bowden 2005; Ishizawar and Parsons 2004; Lau 2005; Shupnik 2004). Based on the inducible c-Src inhibitory properties of tocotrienol one may postulate that tocotrienol has anti-cancer properties. The anti-cancer properties of tocotrienol have been discussed in a separate section below.
GSH is the major cellular thiol present in mammalian cells and is critical for maintenance of redox homeostasis (Sun et al., 2006). GSH is a key survival factor in cells of the nervous system and lowered [GSH]i is one of the early markers of neurotoxicity induced by a variety of agonists (Bains and Shaw 1997; Dringen et al., 2000). We observed that α-tocotrienol clearly protects primary cortical neurons against a number of GSH-lowering neurotoxins (Khanna et al., 2003). Of interest, the neurons survived even in the face of GSH loss. These observations led to the hypothesis that loss of [GSH]i alone is not lethal (Khanna et al., 2003). Given that pro-GSH agents are known to be neuroprotective in a variety of scenarios (Bains and Shaw 1997; Han et al., 1997; Schulz et al., 2000) it becomes reasonable to hypothesize that glutamate-induced lowering of [GSH]i triggers downstream responses that execute cell death. Our works led to the identification of 12-lipoxygenase (12-Lox) as a key tocotrienol-sensitive mediator of neurodegeneration (Khanna et al., 2003). Specific inhibition of 12-Lox by BL15 protected neurons from glutamate-induced degeneration although [GSH]i is compromised by 80%. Similar protective effects of BL15 were noted when BSO, a specific inhibitor of GSH synthesis, was used as the agonist. Importantly, neurons isolated from mice lacking the 12- lipoxygenase gene were observed to be resistant to glutamate-induced loss of viability (Khanna et al., 2003). This key piece of evidence established that indeed 12-Lox represents a critical checkpoint in glutamate-induced neurodegeneration.
Understanding of the intracellular regulation of 12-lipoxygenase requires knowledge of the distribution of both enzyme protein and its activity. For example, in human erythroleukemia cells, the membrane fraction contains about 90% of the total cellular 12-Lox activity, whereas only 10% of 12-Lox activity resides in the cytosol. However, the majority of cellular 12-Lox protein is found in the cytosol (Hagmann et al., 1993). Upon activation, 12-Lox may translocate to the membrane (Hagmann et al., 1993). Consistently, we have observed the decreased presence of 12-Lox in the cytosol and increased presence in the membrane of glutamate-treated cells. For 5-lipoxygenase, both catalytic function and translocation of the enzyme from the cytosol to the membrane are known to be regulated by tyrosine kinases (Lepley et al., 1996). Recently we have noted that 12-Lox is subject to rapid tyrosine phosphorylation in neuronal cells challenged with glutamate or GSH-lowering agents. Such rapid phosphorylation coincides with the timeline of c-Src activation (Khanna et al., 2005b). Inhibitors of c-Src abrogated inducible 12-Lox tyrosine phosphorylation supporting the notion that c-Src may directly phosphorylate 12-Lox in challenged neurons. To test this hypothesis we utilized genetic approaches of over-expressing kinase-active, kinase-dead or dominant negative c-Src in neuronal cells. Findings from cell biology studies as well as from the study of c-Src and 12-Lox in cell-free systems indicate that in response to challenge by glutamate or GSH-lowering agents, c-Src is rapidly activated and phosphorylates 12-Lox.(Khanna et al., 2005b).
Neurons and the brain are rich in arachidonic acid (AA; 20:4ω-6). Massive amounts of AA are released from the membranes in response to brain ischemia or trauma (Bazan 1970; Bazan 1971a; Bazan 1971b; Bazan 1976; Bazan and Rakowski 1970). Subsequent work has established that AA and its metabolites may be neurotoxic. There are three major pathways of AA metabolism: lipoxygenases, cycloxygenases, and cytochrome P450. The cycloxygenase pathway has been preliminarily ruled out from being a contributor to neurodegeneration (Kwon et al., 2005). In the lipoxygenase pathway, metabolites of 12-Lox seem to be the major metabolite of arachidonic acid in the brain (Adesuyi et al., 1985; Carlen et al., 1994) as well as in cultured cortical neurons(Ishizaki and Murota 1991; Miyamoto et al., 1987a; Miyamoto et al., 1987b). Lipoxygenases, mainly 5-, 12- and 15-Lox, are named for their ability to insert molecular oxygen at the 5, 12, or 15-carbon atom of arachidonic acid forming a distinct hydroperoxy-eicosatetraenoic (HPETE) acid (Yamamoto 1992). 12-Lox produces 12(S)-HPETE which is further metabolized into four distinct products: an alcohol [12(S)-HETE], a ketone (12-keto-eicosatetraenoic acid), or two epoxy alcohols (hepoxilin A3 and B3). Immunohistochemical studies revealed the occurrence of 12-Lox in neurons; particularly in hippocampus, striatum, olivary nucleus, as well as in glial and in cerebral endothelial cells (Nishiyama et al., 1992; Nishiyama et al., 1993). Using immature cortical neurons and HT cells, it has been shown that a decrease in [GSH]i triggers the activation of neuronal 12-Lox, which leads to the production of peroxides, the influx of Ca2+, and ultimately to cell death (Li et al., 1997; Tan et al., 2001). The 12-Lox metabolite 12-HPETE proved to be capable of causing cell death (Gu et al., 2001). Inhibition of 12-Lox protected cortical neurons from β-amyloid induced toxicity (Lebeau et al., 2001). Intracellular calcium chelation delayed cell death by lipoxygenase-mediated free radicals in mouse cortical cultures (Wie et al., 2001). In sum, 12-Lox poses clear threat to neuronal survival especially under GSH-deficient conditions.
Lipoxygenase activity is sensitive to vitamin E. α-Tocopherol strongly inhibits purified 5-Lox with a IC50 of 5 μM. The inhibition is independent of the antioxidant property of tocopherol. Tryptic digestion and peptide mapping of the 5-Lox-tocopherol complex indicated that tocopherol binds strongly to a single peptide (Reddanna et al., 1985). Another study reported inhibition of 15-Lox by tocopherol via specific interaction with the enzyme protein (Grossman and Waksman 1984). Of interest, inhibitors specific for cycloxygenase or 5-Lox are not effective in protecting neuronal cells against glutamate-induced death suggesting a specific role of 12-Lox in glutamate-induced death (Khanna et al., 2003; Khanna et al., 2005b). Our studies addressing the effect of α-tocotrienol on pure 12-Lox indicate that α-tocotrienol directly interacts with the enzyme to suppress arachidonic acid metabolism. In silico studies examining possible docking sites of α-tocotrienol to 12-Lox support the presence of a α-tocotrienol binding solvent cavity close to the active site. Previously it has been demonstrated in 15-Lox that COOH terminal of arachidonic acid enters this solvent cavity while accessing the catalytic site (Borngraber et al., 1999). It is therefore plausible that the binding position of α-tocotrienol prevents access of the natural substrate arachidonic acid to the active site of 12-Lox (Khanna et al., 2003). Does 12-Lox have a tangible impact on neurodegenerative processes in vivo? In 1992, it was reported that a mixed lipoxygenase/cyclooxygenase inhibitor SK&F 105809 reduced cerebral edema after closed head injury in rat (Shohami et al., 1992). We noted that 12-Lox, but not 5-Lox (Kitagawa et al., 2004), deficient mice were significantly protected against stroke-related injury of the brain (Khanna et al., 2005b). The case for 12-Lox as an important mediator of neurodegeneration in vivo is gaining additional support from independent studies (Musiek et al., 2006). 12-Lox has been also implicated in the pathogenesis of Alzheimer’s (Yao et al., 2005). α-Tocotrienol is capable of resisting neurodegeneration in vivo by opposing the c-Src and 12-Loxpathways.
Pure and mixed isoprenoids have potent anti-cancer activity (Mo and Elson 1999). As discussed earlier in this work, tocotrienols are isoprenoids but tocopherols are not. Unlike in the case of neuroprotection where α-tocotrienol has emerged to be the most potent isoform (Khanna et al., 2006; Khanna et al., 2005b; Sen et al., 2004; Sen et al., 2006), there seems to somewhat of a consensus that γ- and δ-tocotrienols are the most potent anti-cancer isoform of all natural existing tocotrienols. One of the first studies addressing the role of tocotrienols in neoplastic disorders was reported in 1989 (Komiyama et al., 1989). The effects of intraperitoneally injected α-and γ-tocotrienol, as well as that of α-tocopherol, have been examined. Both tocotrienols were effective against sarcoma 180, Ehrlich carcinoma, and invasive mammary carcinoma. γ-Tocotrienol showed a slight life-prolonging effect in mice with Meth A fibrosarcoma, but the tocotrienols had no antitumor activity against P388 leukemia at doses of 5-40 mg/kg/d (Komiyama et al., 1989). In contrast to tocotrienols, α-tocopherol was not as effective. The antitumor activity of γ-tocotrienol was higher than that of α-tocotrienol. In contrast to α-tocopherol, tocotrienols showed growth inhibition of human and mouse tumor cells when the cells were exposed to these agents for 72 h in vitro (Komiyama et al., 1989). In an independent study published in the same year the anti-carcinogenic properties of palm oil, a rich source of tocotrienols, was reported (Sundram et al., 1989). In this study, young female Sprague-Dawley rats were treated with a single dose of 5 mg of 7,12-dimethylbenz(a)anthracene intragastrically. Three days after carcinogen treatment, the rats were put on semisynthetic diets containing 20% by weight of corn oil, soybean oil, crude palm oil (CPO), refined, bleached, deodorized palm oil (RBD PO) and metabisulfite-treated palm oil (MCPO) for 5 months. During the course of experiments, rats fed on different dietary fats had similar rate of growth. Rats fed 20% corn oil or soybean oil diet had marginally higher tumor incidence than rats fed on palm oil diets. At autopsy, rats fed on high corn oil or soybean oil diets had significantly more tumors than rats fed on the three palm oil diets. Palm oil is different from corn oil and soybean oil in many ways. In addition to possessing higher levels of tocotrienol, palm oil has a contrasting fatty acid profile and also much higher levels of tocopherol and carotenes. As such, the favorable anti-carcinogenic effects noted in this study cannot be directly associated with tocotrienols (Sundram et al., 1989).The antioxidant or redox property of tocotrienol is not responsible for its anti-cancer property. Results in support of this hypothesis show that a redox-silent analogue of α-tocotrienol, 6-O-carboxypropyl-α-tocotrienol is cytotoxic against A549 cells, a human lung adenocarcinoma cell line (Yano et al., 2005). Although the phenolic antioxidant group in tocotrienol may not be implicated in its anticancer property, it is apparent that the phytyl side chain has some antioxidant property which prevents against carcinogenesis (Yu et al., 2005).
Among the various forms of cancer, breast cancer has been most extensively studied in cell culture and rodent in vivo models for the efficacy of tocotrienols. Tocopherol and tocotrienol have been tested side-by-side for chemopreventive activity in a chemically induced rat mammary-tumor model. When mammary tumors were induced by 7,12- dimethylbenz(a)anthracene,only the tocotrienol group showed enhanced tumor latency (Gould et al., 1991). The tocotrienol-rich fraction (TRF) of palm oil is not only rich in tocotrienols but also contains some α-tocopherol. The effects of TRF and α-tocopherol on the proliferation, growth, and plating efficiency of the MDA-MB-435 estrogen-receptor-negative human breast cancer cells have been examined (Nesaretnam et al., 1995). TRF inhibited the proliferation of these cells with a concentration required to inhibit cell proliferation by 50% of 180 microgram/mL whereas α-tocopherol had no effect at concentrations up to 1000 microgram/mL. The effects of TRF and α-tocopherol were also tested in longer-term experiments, using concentrations of 180 and 500 microgram/mL. TRF, but not α-tocopherol, inhibited the growth as well as plating efficiency of the cells. These findings point towards the hypothesis that α-tocopherol contained in the TRF does not account for its beneficial effects and that tocotrienols may have been the active principle responsible for the observed effects of TRF (Nesaretnam et al., 1995). It is now known that TRF, α-, γ- and δ-tocotrienols inhibited proliferation of estrogen receptor-negative MDA-MB-435 human breast cancer cells with 50% inhibitory concentrations (IC50) of 180, 90, 30 and 90 microg/mL, respectively, whereas α-tocopherol is not effective at concentrations up to 500 microg/mL. Tocotrienols inhibit the proliferation of estrogen receptor-positive MCF-7 cells. The IC50s for TRF, α-, γ- and δ-tocotrienols have been estimated to be 4, 6, 2 and 2 microg/mL, respectively. In sharp contrast, the efficiency of α-tocopherol under comparable conditions is 20-50 times lower with a IC50 of 125 microg/mL (Guthrie et al., 1997). Tamoxifen, a widely used synthetic anti-estrogen inhibits the growth of MCF-7 cells with an IC50 of 0.04 microg/mL. In the MCF-7 cells, only 1:1 combinations of γ- or δ-tocotrienol with tamoxifen showed a synergistic inhibitory effect on the proliferative rate and growth of the cells. α-Tocopherol did not exhibit this beneficial synergistic effect with tamoxifen (Guthrie et al., 1997). The inhibition by tocotrienols was not overcome by addition of excess estradiol to the culture medium suggesting that tocotrienols are effective inhibitors of both estrogen receptor-negative and - positive cells and that combinations with tamoxifen may be useful for breast cancer therapy (Guthrie et al., 1997). Studies to come would strengthen support for the case that tocotrienols are effective against breast cancer in vitro. TRF inhibits growth of MCF7 cells in both the presence and absence of estradiol such that complete suppression of growth is achieved at 8 microg/mL. MDA-MB-231 cells are also inhibited by TRF such that 20 microg/mL TRF is needed for complete growth suppression. The study of the individual component tocotrienols in TRF revealed that all fractions inhibit growth of both estrogen-responsive as well as estrogen-nonresponsive cells and of estrogen-responsive cells in both the presence and absence of estradiol. This estradiol-independent effect of tocotrienols is of clinical interest (Nesaretnam et al., 2000; Nesaretnam et al., 1998). γ- and δ-Tocotrienol fractions were most potent inhibitors of breast cancer cell growth. Complete inhibition of MCF7 cell growth was achieved at 6 microg/mL of γ-tocotrienol/δ-tocotrienol in the absence of estradiol and 10 microg/mL of δ-tocotrienol in the presence of estradiol. In contrast, complete suppression of MDA-MB-231 cell growth was not achieved even at concentrations of 10 microg/mL of δ-tocotrienol. Of note, unlike tocotrienols α-tocopherol does not inhibit MCF7, MDA-MB-231 or ZR-75-1 cell growth in either the presence or the absence of estradiol (Mo and Elson 1999; Nesaretnam et al., 2000; Nesaretnam et al., 1998). Studies examining the mechanisms by which tocotrienols check the growth of breast cancer cells have identified that tocotrienols do not act via an estrogen receptor-mediated pathway and must therefore act differently from estrogen antagonists. Furthermore, tocotrienols did not increase levels of growth-inhibitory insulin-like growth factor binding proteins in MCF7 cells, implying also a different mechanism from that proposed for retinoic acid inhibition of estrogen-responsive breast cancer cell growth (Nesaretnam et al., 1998).
Unlike α-tocopherol, δ-tocopherol seems to be more promising albeit much less so than the tocotrienols. The apoptosis-inducing properties of RRR-α-, β-, γ-, and δ-tocopherols, and α-, γ-, and δ-tocotrienols have been compared in estrogen-responsive MCF7 and estrogen-nonresponsive MDA-MB-435 human breast cancer cell lines. Vitamin E succinate, a known inducer of apoptosis in several cell lines, including human breast cancer cells, served as a positive control. The estrogen-responsive MCF7 cells was found to be more susceptible than the estrogen-nonresponsive MDA-MB-435 cells, with concentrations for half-maximal response for tocotrienols (α, γ, and δ) and RRR-δ-tocopherol of 14, 15, 7, and 97 micrograms/ml, respectively. The tocotrienols (α, γ, and δ) and RRR-δ-tocopherol induced MDA-MB-435 cells to undergo apoptosis, with concentrations for half-maximal response of 176, 28, 13, and 145 micrograms/ml, respectively. With the exception of RRR-δ-tocopherol, the tocopherols (α, β, and γ) and the acetate derivative of RRR-α-tocopherol (RRR-α-tocopheryl acetate) were ineffective in induction of apoptosis in both cell lines when tested within the range of their solubility, i.e., 10-200 micrograms/ml (Yu et al., 1999)
Mammary tissue homeostasis depends upon dynamic interactions between the epithelial cells, their microenvironment (including the basement membrane and the stroma), and the tissue architecture, which influence each other reciprocally to regulate growth, death and differentiation in the gland. The study of normal mammary epithelial cells isolated from mid-pregnant mice grown in collagen gels and maintained on serum-free media showed that treatment with 0-120 microM α- or γ-tocopherol had no effect, whereas 12.5-100 microM TRF, 100-120 microM δ-tocopherol, 50-60 microM α-tocotrienol, and 8-14 microM γ- or δ-tocotrienol significantly inhibited cell growth in a dose-responsive manner. In acute studies, 24h exposure to 0-250 microM α-, γ-, and δ-tocopherol had no effect, whereas similar treatment with 100-250 microM TRF, 140-250 microM α-, 25-100 microM γ- or δ-tocotrienol significantly reduced cell viability. The observed growth-inhibitory doses of TRF, δ-tocopherol, and α-, γ-, and δ-tocotrienol induced apoptosis in these cells. Mammary epithelial cells preferentially took up tocotrienols as compared to tocopherols, suggesting that at least part of the reason tocotrienols display greater potency than tocopherols is because of greater cellular uptake. These observations suggest that the highly biopotent γ- and δ-tocotrienol isoforms may play a physiological role in modulating normal mammary gland growth, function, and remodeling (McIntyre et al., 2000b). A later study identified that highly malignant cells are specifically more sensitive, whereas the preneoplastic cells are least sensitive to the antiproliferative and apoptotic effects of tocotrienols (McIntyre et al., 2000a). The comparative effects of tocopherols and tocotrienols were examined using preneoplastic (CL-S1), neoplastic (-SA), and highly malignant (+SA) mouse mammary epithelial cells. Over a five-day culture period, treatment with 0-120 microM α- and γ-tocopherol had no effect on cell proliferation, whereas cell growth was inhibited 50% (IC50) as compared with controls by treatment with the following: 13, 7, and 6 microM tocotrienol-rich-fraction of palm oil (TRF); 55, 47, and 23 microM δ-tocopherol; 12, 7, and 5 microM α-tocotrienol; 8, 5, and 4 microM γ-tocotrienol; or 7, 4, and 3 microM δ-tocotrienol in CL-S1, -SA and +SA cells, respectively. Acute 24-hr exposure to 0-250 microM α- or γ-tocopherol (CL-S1, -SA, and +SA) or 0-250 microM δ-tocopherol (CL-S1) had no effect on cell viability, whereas cell viability was reduced 50% (LD50) as compared with controls by treatment with 166 or 125 microM δ-tocopherol in -SA and +SA cells, respectively. Additional LD50 doses were determined as the following: 50, 43, and 38 microM TRF; 27, 28, and 23 microM α-tocotrienol; 19, 17, and 14 microM γ-tocotrienol; or 16, 15, or 12 microM δ-tocotrienol in CL-S1, -SA, and +SA cells, respectively. Treatment-induced cell death resulted from activation of apoptosis. Consistent with previous observations, CL-S1, -SA, and +SA cells preferentially accumulated tocotrienols as compared with tocopherols. Highly malignant +SA cells were the most sensitive, whereas the pre-neoplastic CL-S1 cells were the least sensitive to the anti-proliferative and apoptotic effects of tocotrienols (McIntyre et al., 2000a).
How do tocotrienols induce apoptosis in breast cancer cells? δ-Tocotrienol induces TGF-β receptor II expression and activates TGF-β-, Fas- and JNK-signaling pathways. (Shun et al., 2004). Are the caspase-3,8,9 pathways involved in tocotrienol-induced death of cancer cells? To respond to this question, highly malignant +SA mouse mammary epithelial cells were grown in culture and maintained on serum-free media. Treatment with TRF or γ-tocotrienol, but not α-tocopherol, induced a dose-dependent decrease in +SA cell viability (Shah et al., 2003). TRF- and γ-tocotrienol-induced cell death resulted from apoptosis. Treatment of cells with TRF or γ-tocotrienol increased intracellular activity and levels of processed caspase-8 and -3 but not caspase-9. Furthermore, treatment with specific caspase-8 or -3 inhibitors, but not caspase-9 inhibitor, completely blocked tocotrienol-induced apoptosis in +SA cells suggesting that tocotrienol-induced apoptosis in +SA mammary cancer cells is mediated through activation of the caspase-8 signaling pathway and is independent of caspase-9 activation (Shah et al., 2003). Tocotrienol-induced caspase 8 activation is not associated with death receptor apoptotic signaling (Shah and Sylvester 2004). γ-Tocotrienol significantly decreases the relative intracellular levels of phospho-phosphatidylinositol 3-kinase (PI3K)-dependent kinase 1 (phospho-PDK-1 active), phospho-Akt (active), and phospho-glycogen synthase kinase3. It also decreases the intracellular levels of FLICE-inhibitory protein (FLIP), an antiapoptotic protein that inhibits caspase-8 activation. Because stimulation of the PI3K/PDK/Akt mitogenic pathway is associated with increased FLIP expression, enhanced cellular proliferation, and survival, these observations suggest that tocotrienol-induced caspase-8 activation and apoptosis in malignant +SA mammary epithelial cells is associated with a suppression in PI3K/PDK-1/Akt mitogenic signaling and subsequent reduction in intracellular FLIP levels (Shah and Sylvester 2004). More recently it has been reported that the antiproliferative effects of γ-tocotrienol results, at least in part, from a reduction in Akt and NFkappaB activity in neoplastic +SA mammary epithelial cells (Shah and Sylvester 2005a).
α-Tocotrienol (20 microM) seems to share some of the cytotoxic effects on cancer cells by inducing caspase-8 and caspase-3 activity (Sylvester and Shah 2005a). Combined treatment with specific caspase-8 or caspase-3 inhibitors completely blocked α-tocotrienol-induced apoptosis and caspase-8 or caspase-3 activity, respectively. In contrast, α-tocotrienol treatment had no effect on caspase-9 activation, and combined treatment with a specific caspase-9 inhibitor did not block α-tocotrienol-induced apoptosis in +SA cells. α-Tocotrienol-induced caspase-8 activation and apoptosis is not mediated through death receptor activation in malignant +SA mammary epithelial cells. Tocotrienol-induced caspase-8 activation and apoptosis in malignant +SA mammary epithelial cells is not mediated through the activation of death receptors, but appears to result from the suppression of the PI3K/PDK/Akt mitogenic signaling pathway, and subsequent reduction in intracellular FLIP expression (Sylvester and Shah 2005a).
Bcl-2 family proteins tightly control apoptosis by regulating the permeabilization of the mitochondrial outer membrane and, hence, the release of cytochrome c and other proapoptotic factors. Is tocotrienol-induced apoptosis of cancer cells dependent on mitochondrial pathways? Incubation of MDA-MB-231cells with γ-tocotrienol causes membrane blebbing, formation of apoptotic bodies, chromatin condensation/fragmentation, and phosphatidylserine externalization (Takahashi and Loo 2004). These are all hallmarks of apoptosis. In γ-tocotrienol-treated cells, mitochondria were disrupted. Collapse of the mitochondrial membrane potential was followed by the release of mitochondrial cytochrome c. However, the expression of Bax and Bcl-2 mRNA and protein did not change. In contrast to other studies reporting that tocotrienol-induced cell death is caspase dependent (Shah et al., 2003; Shah and Sylvester 2004), it was noted that in this model caspases were not involved in γ-tocotrienol-induced apoptosis (Takahashi and Loo 2004). In a study of +SA cells it was noted that although γ-tocotrienol induced apoptosis it did not disrupt mitochondrial membrane potential, or cause the release of mitochondrial cytochrome c into the cytoplasm. Tocotrienol-treated apoptotic +SA cells showed a paradoxical decrease in mitochondrial levels of pro-apoptotic proteins Bid, Bax, and Bad, and a corresponding increase in mitochondrial levels of anti-apoptotic proteins, Bcl-2 and Bcl-xL, suggesting that mitochondrial membrane stability and integrity might actually be enhanced for a limited period of time following acute tocotrienol exposure. This significance of this unusual finding remains obscure (Shah and Sylvester 2005b)
Over the past 30 years, a relatively simple growth factor and its cognate receptor have provided seminal insights into the understanding of the genetic basis of cancer, as well as growth factor signaling. The epidermal growth factor (EGF), its cognate receptor (EGFR) and related family members have been shown to be important in normal, as well as the malignant growth of many cell types including breast cancer. EGF is a potent mitogen for normal and neoplastic mammary epithelial cells. Initial events in EGFR mitogenic-signaling are G-protein activation, stimulation of adenylyl cyclase and cyclic AMP (cAMP) production. Do the antiproliferative effects of tocotrienols associate with reduced EGF-induced G-protein and cAMP-dependent mitogenic signaling? To answer this question, preneoplastic CL-S1 mouse mammary epithelial cells were grown in culture and maintained on serum-free media containing 0-25 micro mol/L tocotrienol-rich fraction of palm oil and/or different doses of pharmacological agents that alter intracellular cAMP levels. Tocotrienol-induced effects on EGF-receptor levels of tyrosine kinase activity, as well as EGF-dependent mitogen-activated pathway kinase (MAPK) and Akt activation, were examined. It was noted that the anti-proliferative effects of tocotrienols in pre-neoplastic mammary epithelial cells do not reflect a reduction in EGF-receptor mitogenic responsiveness, but rather, result from an inhibition in early post-receptor events involved in cAMP production upstream from EGF-dependent MAPK and phosphoinositide 3-kinase/Akt mitogenic signaling (Sylvester et al., 2002).
7,12-Dimethylbenz[a]anthracene (DMBA) is a potent inducer breast cancer in rats. The anti-tumour and anti-cholesterol impacts of has been examined in rats treated with the chemical carcinogen DMBA, which is known to induce mammary carcinogenesis and hypercholesterolemia. DMBA induced multiple tumors on mammary glands after 6 months. Feeding of TRF (10 mg/kg body weight/day) for 6 months, isolated from rice bran oil, to DMBA-administered rats, attenuated the severity and extent of neoplastic transformation in the mammary glands. Consistently, plasma and mammary alkaline phosphatase activities increased during carcinogenesis, were significantly decreased in TRF-treated rats. TRF treatment to rats maintained low levels of glutathione S-transferase activities in liver and mammary glands, which is consistent with the anti-carcinogenic properties of TRF (Iqbal et al., 2003). Administration of DMBA also caused a significant increase of 30% in plasma total cholesterol and 111% in LDL-cholesterol levels compared with normal control levels. Feeding of TRF to rats caused a significant decline of 30% in total cholesterol and 67% in LDL-cholesterol levels compared with the DMBA-administered rats. The experimental hypercholesterolaemia caused a significant increase in enzymatic activity (23%) and protein mass (28%) of hepatic 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase. Consistent with TRF-mediated reduction in plasma lipid levels, enzymatic activity and protein mass of HMG-CoA reductase was significantly reduced. These observations support that TRF has potent anti-cancer and anti-cholesterol effects in rats (Iqbal et al., 2003).
Tocotrienols act on cell proliferation in a dose-dependent manner and can induce programmed cell death in breast cancer cells. To elucidate the molecular basis of the effect of tocotrienols, MCF-7 breast cancer cells were injected into athymic nude mice. Feeding quite large amounts (1mg/d) of TRF for 20 weeks delayed the onset, incidence, and size of tumors. At autopsy, the tumor tissue was excised and cDNA array analysis was performed. Thirty out of 1176 genes were significantly affected by TRF. Ten genes were down-regulated and 20 genes up-regulated with respect to untreated animals. The expression of the interferon-inducible transmembrane protein-1 gene was significantly up-regulated in tumors excised from TRF-treated animals compared with control mice. Within the group of genes related to the immune system, CD59 glycoprotein precursor gene was up-regulated. Among the functional class of intracellular transducers/effectors/modulators, the c-myc gene was significantly down-regulated in tumors in response to TRF treatment. This work on the survey of TRF-sensitive genes in the tumor in vivo presented useful insight (Nesaretnam et al., 2004).
Unlike the literature on breast cancer cells, work on prostate cancer cells investigating the effect of tocotrienol is scant. In a model where prostate cancer was induced by injecting PC3 cells into nude BALB/c mice, it has been noted that the radiotherapy efficacy of prostate cancer can be increased with γ-tocotrienol and a pro-oxidant if the kidneys can be shielded (Kumar et al., 2006). When the tumors were about 5 mm in diameter, mice were injected subcutaneously with 400 mg/kg γ-tocotrienol and irradiated 24 h later at the site of the tumor with a dose of 12 Gy (60) Cobalt. The size of the tumors was reduced by almost 40%, but only in tocotrienol-treated and irradiated mice (Kumar et al., 2006). The growth-inhibitory and apoptotic effects of TRF has been tested on normal human prostate epithelial cells (PrEC), virally transformed normal human prostate epithelial cells (PZ-HPV-7), and human prostate cancer cells (LNCaP, DU145, and PC-3) (Srivastava and Gupta 2006). TRF selectively resulted in potent growth inhibition in cancer cells but not normal cells. In response to TRF, cancer cells underwent G0/G1 phase arrest and sub G1 accumulation. Colony formation by all three prostate cancer cell lines studied was clearly arrested by TRF. The IC(50) after 24h TRF treatment in LNCaP, PC-3, and DU145 cells were in the order 16.5, 17.5, and 22.0 microg/ml. TRF treatment resulted in significant apoptosis of cancer cells but not of normal cells (Srivastava and Gupta 2006).
Inhibition of tumor promotion by tocopherols and tocotrienols was examined by an in vitro assay utilizing the activation of Epstein-Barr virus early antigen expression in Epstein-Barr virus genome-carrying human lymphoblastoid cells. γ- and δ-Tocotrienols derived from palm oil exhibited a strong activity against tumor promotion by inhibiting Epstein-Barr virus early antigen expression in Raji cells induced by 12-O-tetradecanoylphorbol-13-acetate. In contrast, the corresponding tocopherols lacked this activity (Goh et al., 1994).
Tocotrienol inhibits the growth of hepatoma cells but not that of hepatocytes from healthy rat liver (Sakai et al., 2004). Consistently, tocotrienol killed murine liver cancer cells but not normal cells (Har and Keong 2005). Of note, this interesting function of tocotrienol is not shared by tocopherol. Tocotrienol induced apoptosis of hepatoma cells is mediated by caspase 3 activation. In addition, tocotrienol induced caspase 8 activity. An inhibitor of caspase 8 suppressed the induction of apoptosis in hepatoma by tocotrienol. Compared to tocopherol, tocotrienol was more quickly taken up by the cancer cells suggesting that this could be one reason why tocotrienol was so effective in killing the hepatoma cells (Har and Keong 2005; Sakai et al., 2004). γ-Tocotrienol inhibits the proliferation of human hepatoma Hep3B cells at lower concentrations and shorter treatment times than α-tocotrienol. γ-Tocotrienol induces poly (ADP-ribose) polymerase (PARP) cleavage activating caspase-3. In addition, γ-tocotrienol activates caspase-8 and caspase-9 and up-regulates Bax and fragments of Bid (Sakai et al., 2005). In human hepatocellular carcinoma HepG2 cells, δ-tocotrienol exerts more significant anti-proliferative effect than α-, β-, and γ-tocotrienols. δ-Tocotrienol induced apoptosis, and also tended to induce S phase arrest. The phase I enzyme CYP1A1 was induced by δ-tocotrienol (Wada et al., 2005).
2-Acetylaminofluorene is a potent hepatocarcinogen. Prolonged feeding of rats with 2-acetylaminofluorene causes hepatocellular damage. Such damage is prevented by tocotrienol supplementation (Ngah et al., 1991). 2-Acetylaminofluorene significantly increased the activities of both plasma and liver microsomal γ-glutamyltranspeptidase (GGT) and liver microsomal UDP-glucuronyltransferase (UDP-GT). Tocotrienols administered together with AAF significantly decrease the activities of plasma GGT after 12 and 20 wk and liver microsomal UDP-GT after 20 wk when compared with matched controls (Ngah et al., 1991). In a scenario of stronger chemical carcinogen insult caused by 2-acetylaminofluorene in conjunction with diethylnitrosamine the effects of tocotrienol turned out to be more encouraging. In response to challenge by the chemical carcinogens all ten rats in the group showed the presence of two grayish white nodules in the liver. Rats subjected to long-term administration of tocotrienol were protected. Only one out of six rats studied in this group had the hepatocarcinoma (Rahmat et al., 1993)
The anticancer efficacy of TRF has been evaluated during diethylnitrosamine (DEN)/2-acetylaminofluorene (AAF)-induced hepatocarcinogenesis in male Sprague-Dawley rats. TRF treatment was carried out for 6 months, and was started 2 weeks before the initiation phase of hepatocarcinogenesis. Morphological examination of the livers from DEN/AAF rats showed numerous off-white patches and few small nodules, which were significantly reduced by TRF treatment. DEN/AAF caused a two-fold increase in the activity of alkaline phosphatase in the plasma as compared with normal control rats. This increase of the tissue damage marker was prevented significantly by TRF treatment. Hepatic activity of glutathione S-transferase was also increased (3.5-fold) during the induction of hepatic carcinogenesis. Lipid peroxidation and low-density lipoprotein oxidation increased three-fold following initiation by DEN/AAF as compared with normal control rats. TRF treatment to DEN/AAF-treated rats substantially decreased (62-66%) the above parameters and thus limited the action of DEN/AAF. Thus, TRF exhibited clear protective properties in this model of chemical carcinogenesis (Iqbal et al., 2004).
RKO, a poorly differentiated colon carcinoma cell line, represents a commonly used in vitro model for human colon carcinoma. RKO cells contain wild-type p53 but lack endogenous human thyroid receptor nuclear receptor (h-TRbeta1). In a dose- and time- dependent manner TRF inhibited the growth and colony formation of RKO. In addition, TRF induced WAF1/p21 which appeared to be independent of cell cycle regulation and was transcriptionally up-regulated in p53 dependent fashion. TRF treatment also resulted in alteration in Bax/Bcl2 ratio in favor of apoptosis, which was associated with the release of cytochrome c and induction of apoptotic protease-activating factor-1. This altered expression of Bcl2 family members triggered the activation of initiator caspase-9 followed by activation of effector caspase-3. Thus, in RKO cells the pathways involved in TRF-induced apoptosis is fairly well characterized (Agarwal et al., 2004). Since the discovery that telomerase is repressed in most normal human somatic cells but strongly expressed in most human tumors, telomerase emerged as an attractive target for diagnostic, prognostic and therapeutic purposes to combat human cancer (Shay and Wright 2006). Tocotrienol has been noted to inhibit telomerase activity of DLD-1 human colorectal adenocarcinoma cells in a time- and dose-dependent manner. δ-Tocotrienol demonstrated the highest inhibitory activity. Tocotrienol inhibited protein kinase C activity, resulting in down-regulation of c-myc and human telomerase reverse transcriptase (hTERT) expression, thereby reducing telomerase activity. Of note, tocopherol does not share the potent activity of tocotrienol in this regard (Shay and Wright 2006).
How much tocotrienol is needed to inhibit the increase in population of murine B16(F10) melanoma cells during a 48-h incubation by 50% (IC50 value)? The IC50 value estimated for farnesol, the side-chain analog of the tocotrienols (50 micromol/L) falls midway between that of α-tocotrienol (110 micromol/L) and those estimated for γ- (20 micromol/L) and δ- (10 micromol/L) tocotrienol. Experimental diets were fed to weanling C57BL female mice for 10 d prior to and 28 d following the implantation of the aggressively growing and highly metastatic B16(F10) melanoma. The isomolar (116 micromol/kg diet) and the vitamin E-equivalent (928 micromol/kg diet) substitution of d-γ-tocotrienol for dl-α-tocopherol in the AIN-76A diet produced 36 and 50% retardations, respectively, in tumor growth. Thus, in this skin melanoma model both tocotrienol as well as tocopherol were significantly effective (He et al., 1997). The growth suppressive effects of γ-tocotrienol on murine B16(F10) melanoma cells have been independently reproduced (Mo and Elson 1999).
Recent works have led to the identification of anti-angiogenic properties of tocotrienol (see Table 1). This novel development warrants further research testing the anti-cancer effects of tocotrienol in vivo.
That the α-tocotrienol form of natural vitamin E, not tocopherol, may have significant cholesterol-lowering properties represents one of the early findings describing the unique biological properties of tocotrienol that was reported two decades ago (Qureshi et al., 1986). The endoplasmic reticulum enzyme 3-hydroxy-3-methylglutaryl (HMG-CoA) CoA reductase produces mevalonate, which is converted to sterols and other products. It is proposed that tocotrienols are effective in lowering serum total and LDL-cholesterol levels by inhibiting the hepatic enzymic activity of HMG-CoA reductase through a post-transcriptional mechanism. α-Tocopherol, however, has an opposite effect (induces) on this enzyme activity (Qureshi et al., 2002). This contrast is of outstanding significance and requires further characterization. α-Tocotrienol, contained in the oily non-polar fraction of high protein barley (Hordeum vulgare L.) flour, decreased hepatic cholesterogenesis and serum total and low density lipoprotein cholesterol and concomitantly increased lipogenic activity when added to chick diet. It was suspected that the isoprenoid side-chain of tocotrienol was responsible for the observed inhibition of cholesterogenesis (Qureshi et al., 1986). Evidence that TRF may indeed lower plasma cholesterol in mammals came from a study of normolipemic and genetically hypercholesterolemic pigs of defined lipoprotein genotype (Qureshi et al., 1991a). The pigs were fed a standard diet supplemented with 50 micrograms/g TRF isolated from palm oil. Hypercholesterolemic pigs fed the TRF supplement showed a 44% decrease in total serum cholesterol, a 60% decrease in LDL-cholesterol, and significant decreases in levels of apolipoprotein B (26%), thromboxane-B2 (41%), and platelet factor 4 (PF4; 29%). It was thus noted that TRF had a marked protective effect on the endothelium and platelet aggregation. The effect of the lipid-lowering diet persisted only in the hypercholesterolemic swine after 8 week feeding of the control diet (Qureshi et al., 1991a). These interesting observations were quickly put to test in humans by means of a double-blind, crossover, 8-week study (Qureshi et al., 1991b). The goal was to compare effects of the tocotrienol-enriched fraction of palm oil (200 mg palmvitee capsules/day) with those of 300 mg corn oil/d on serum lipids of hypercholesterolemic human subjects (serum cholesterol 6.21-8.02 mmol/L). Concentrations of serum total cholesterol (-15%), LDL cholesterol (-8%), Apo B (-10%), thromboxane (-25%), platelet factor 4 (-16%), and glucose (-12%) decreased significantly only in the 15 subjects given palmvitee during the initial 4 wk. Results from the crossover study established that the noted beneficial effects were indeed caused by palmvitee. A carry-over effect of palmvitee was reported. Serum cholesterol concentrations of seven hypercholesterolemic subjects (>7.84 mmol/L) decreased 31% during a 4 wk period in which they were given 200 mg γ-tocotrienol/d. These results suggested that γ-tocotrienol could be the active principle cholesterol inhibitor in palmvitee capsules (Qureshi et al., 1991b). Experimental data from the study of hamsters are in agreement (Raederstorff et al., 2002). What added to the interest in tocotrienol as a cholesterol-lowering nutrient in humans was a concurrent independent study reporting the hypocholesterolemic effects of palmvitee (Tan et al., 1991). Each palmvitee capsule contained approximately 18, 42, and 240 mg of tocopherols, tocotrienols, and palm olein, respectively. All volunteers took one palmvitee capsule per day for 30 consecutive days. Overnight fasting blood was recorded from each volunteer before and after the experiment. Palmvitee lowered both serum total cholesterol and low-density-lipoprotein cholesterol concentrations in all subjects. The magnitude of reduction of serum total cholesterol ranged from 5.0% to 35.9% whereas the reduction of low-density-lipoprotein cholesterol values ranged from 0.9% to 37.0% when compared with their respective baseline values (Tan et al., 1991). In another study, the cholesterol-lowering effects of palmvitee and γ-tocotrienol were examined in hypercholesterolemic subjects after acclimation to the American Heart Association Step 1 dietary regimen for four and eight weeks, respectively (Qureshi et al., 1995). The four-week dietary regimen alone elicited a 5% significant decrease in the cholesterol level of the 36 subjects. Subjects continuing on the dietary regimen for a second four-week period benefited from an additional 2% decrease in their cholesterol levels. The subjects experienced significant palmvitee- and γ-tocotrienol-mediated decreases in plasma cholesterol. The group of subjects acclimated to the dietary regimen for four weeks responded to palmvitee with a 10% statistically significant decrease in cholesterol. Of interest, α-tocopherol attenuated the cholesterol-suppressive action of the tocotrienols. This antagonism between tocopherol and tocotrienol warrants further research. The second group of subjects acclimated to the dietary regimen for eight weeks, received 200 mg γ-tocotrienol/d for four weeks. The cholesterol-suppressive potency of this α-tocopherol-free preparation was calculated to be equivalent to that of the mixture of tocotrienols (220 mg) used in the prior study. Cholesterol levels of the 16 subjects in the second group significantly decreased by 13% during the four-week trial. Plasma apolipoprotein B and ex vivo generation of thromboxane B2 were similarly responsive to the tocotrienol preparations, whereas neither preparation had an impact on high density lipoprotein cholesterol and apolipoprotein A-1 levels (Qureshi et al., 1995).
Tocotrienol not only of palm oil origin but also isolated from rice bran show cholesterol-lowering properties (Chen and Cheng 2006; Qureshi et al., 2001a). A human study with 28 hypercholesterolemic subjects has been executed in 5 phases of 35 days each. The goal was to check the efficacy of a TRF preparation from rice bran alone and in combination with lovastatin. After placing subjects on the American Heart Association (AHA) Step-1 diet (phase II), the subjects were divided into two groups, A and B. The AHA Step-1 diet was continued in combination with other treatments during phases III to V. Group A subjects were given 10 mg lovastatin, 10 mg lovastatin plus 50 mg TRF, 10 mg lovastatin plus 50 mg α-tocopherol per day, in the third, fourth, and fifth phases, respectively. Group B subjects were treated exactly according to the same protocol except that in the third phase, they were given 50 mg TRF instead of lovastatin. The TRF or lovastatin plus AHA Step-1 diet effectively lowered serum total cholesterol (14%, 13%) and LDL-cholesterol (18%, 15%), respectively. The combination of TRF and lovastatin plus AHA Step-1 diet significantly reduced the lipid parameters by 20-25%. Especially significant were the increase in the HDL/LDL ratio to 46% in group A and 53% in group B. None of the subjects reported any side-effects throughout the study of 25 weeks (Qureshi et al., 2001c). Consistent results were obtained using rice-bran derived TRF in another human study (Qureshi et al., 2002). A dose of 100 mg/day of TRF decreased the level of serum total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides compared with the baseline values. The work led to the suggestion that a dose of 100 mg/day TRF plus AHA Step-1 diet could control the risk of coronary heart disease in hypercholesterolemic humans (Qureshi et al., 2002).
Mechanistic evidence supporting the cholesterol-lowering properties of tocotrienol is considerable. Tocotrienols cause post-transcriptional suppression of HMG-CoA reductase by a process distinct from other known inhibitors of cholesterol biosynthesis (Pearce et al., 1992). In addition, γ-tocotrienol may stimulate cholesterol catabolism (Chen and Cheng 2006). In vitro, γ-tocotrienol possesses 30-fold greater activity toward cholesterol biosynthesis inhibition compared to α-tocotrienol. The synthetic (racemic) and natural (chiral) tocotrienols exhibited nearly identical cholesterol biosynthesis inhibition and HMG-CoA reductase suppression properties (Pearce et al., 1992). Incubation of several cell-types with γ-tocotrienol inhibits the rate of [14C]acetate but not [3H] mevalonate incorporation into cholesterol in a concentration- and time-dependent manner, with 50% inhibition at approximately 2 microM and maximum approximately 80% inhibition observed within 6 h in HepG2 cells (Parker et al., 1993). Both HMG-CoA reductase activity and protein expression are sensitive to tocotrienol. In vivo studies lend support to that in vitro observation (Iqbal et al., 2003). Tocotrienols influence the mevalonate pathway in mammalian cells by post-transcriptional suppression of HMG-CoA reductase, and specifically modulate the intracellular mechanism for controlled degradation of the reductase protein, an activity that mirrors the actions of the putative non-sterol isoprenoid regulators derived from mevalonate (Parker et al., 1993). It is suggested that the farnesyl side chain and the methyl/hydroxy substitution pattern of γ-tocotrienol deliver a high level of HMG-CoA reductase suppression, unsurpassed by synthetic analogues studied (Pearce et al., 1994). HMG-CoA reductase activity in tumor tissues differs from that of liver in being resistant to sterol feedback regulation. Tumor reductase activity retains sensitivity to the post-transcriptional regulation. As a consequence, tocotrienol is effective in suppressing mevalonate synthesis. By doing so, tocotrienol can deplete tumor tissues of two intermediate products, farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are incorporated post-translationally into growth control-associated proteins (Elson and Qureshi 1995).
Ubiquitination followed by rapid degradation by 26S proteasomes represents a key mechanism to silence HMG-CoA reductase. This pathway is activated when sterols and non-sterol end products of mevalonate metabolism accumulate in cells. Sterol-accelerated ubiquitination of HMG-CoA reductase requires Insig-1 and Insig-2, membrane-bound proteins of the endoplasmic reticulum (Sever et al., 2003). Recently it has been elegantly demonstrated that δ-tocotrienol stimulates the ubiquitination and degradation of HMG-CoA reductase and blocks processing of sterol regulatory element-binding proteins, another sterol-mediated action of Insigs. The γ-tocotrienol analog was noted to be more selective in enhancing reductase ubiquitination and degradation than blocking the processing of sterol regulatory element-binding proteins. Interestingly, other forms of vitamin E neither accelerate reductase degradation nor block the processing of sterol regulatory element-binding proteins. δ- and γ-Tocotrienol trigger reductase ubiquitination directly and do not require further metabolism for their activity (Song and Debose-Boyd 2006).
Often, the term vitamin E is synonymously used with α-tocopherol. While the expression is correct it is incomplete and may be often misleading. d-α-Tocopherol (RRR-α-tocopherol) has the highest bioavailability and is the standard against which all the others must be compared. However, it is only one out of eight natural forms of vitamin E. The rapidly expanding body of evidence indicating that members of the vitamin E family are functionally unique calls for a revisit of the current practices in vitamin E research and consumption. Research claims should be limited to the specific form of vitamin E studied. For example, evidence for toxicity of a specific form of tocopherol in excess may not be used to conclude that high-dosage vitamin E supplementation may increase all-cause mortality (Miller et al., 2005). Along these lines, it may not be prudent to express frustrations about the net yield of vitamin E research as a whole (Greenberg 2005) when all that has been tested for efficacy on a limited basis in clinical trials is α-tocopherol- just one out of eight forms. Recently it has been suggested that the safe dose of various tocotrienols for human consumption is 200-1000 mg/d (Yu et al., 2006). Vitamin E represents one of the most fascinating natural resources that have the potential to influence a broad range of mechanisms underlying human health and disease. Yet, clinical outcomes studies have failed to meet expectations (Friedrich 2004; Greenberg 2005). The current state of knowledge warrants strategic investment into the lesser known forms of vitamin E with emphasis on uncovering the specific conditions that govern the function of vitamin E molecules in vivo. Outcome studies designed in light of such information would yield lucrative returns.
Tocotrienol research in the laboratory is supported by NIH RO1NS42617.